
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>The Royal College of Physicians is looking at relations between doctors and the drug industry and wants to hear from you (doi: 10.1136/bmj.39428.617431.DB). In case you need them, here are some pointers from this week’s BMJ . Firstly, should we fear for the integrity of medical research because clinical trials are overwhelmingly funded by industry? Yes, says Paulo Bruzzi (doi 10.1136/bmj.39416.559942.BE). Industry designs trials mainly to get new drugs registered as soon as possible, preferably with an unrestricted indication. The best trials for this—in large unselected populations—often leave key questions unanswered and, because of ethical constraints on subsequent trials, unanswerable. Bruzzi is only …
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 6 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
